These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 8819246)

  • 21. Impact of infusion speed on the safety and effectiveness of prothrombin complex concentrate: a prospective clinical trial of emergency anticoagulation reversal.
    Pabinger I; Tiede A; Kalina U; Knaub S; Germann R; Ostermann H;
    Ann Hematol; 2010 Mar; 89(3):309-16. PubMed ID: 19787352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic correction of thrombin generation in dilution-induced coagulopathy: computational analysis based on a data set of healthy subjects.
    Mitrophanov AY; Rosendaal FR; Reifman J
    J Trauma Acute Care Surg; 2012 Aug; 73(2 Suppl 1):S95-S102. PubMed ID: 22847103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of prothrombin as a major thrombogenic agent in prothrombin complex concentrates.
    Dusel CH; Grundmann C; Eich S; Seitz R; König H
    Blood Coagul Fibrinolysis; 2004 Jul; 15(5):405-11. PubMed ID: 15205589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo models of thrombogenic potential: usefulness and limitations.
    MacGregor I; McLaughlin L; Drummond O; Prowse C; Ferguson J
    Acta Haematol; 1995; 94 Suppl 1():18-23; discussion 24. PubMed ID: 7571990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Non-activated and activated prothrombin complex concentrates, Proplex and Feiba, in the treatment of a hemophilia B patient with high titer inhibitor against factor IX].
    Niiya K; Hirose S; Taguchi H; Miyoshi I
    Rinsho Ketsueki; 1985 Jun; 26(6):980-4. PubMed ID: 3877825
    [No Abstract]   [Full Text] [Related]  

  • 26. Successful emergency reversal of phenprocoumon anticoagulation with prothrombin complex concentrate: a prospective clinical study.
    Lorenz R; Kienast J; Otto U; Kiehl M; Schreiter D; Haertel S; Barthels M
    Blood Coagul Fibrinolysis; 2007 Sep; 18(6):565-70. PubMed ID: 17762533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of potential thrombogenicity of coagulation factor IX concentrates in an in vitro model of human thrombogenesis.
    Galan AM; Reverter JC; Bozzo J; Hernandez MR; Escolar G; Aznar-Salatti J
    Thromb Res; 1999 Dec; 96(5):383-9. PubMed ID: 10605953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Levels of prothrombin activation peptide F1+2 in patients with a bleeding tendency.
    Ingerslev J; Holm M; Christiansen K; Knudsen L; Négrier C
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S129-34. PubMed ID: 9819044
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factor IX from prothrombin complex concentrate augments low dose tissue factor-triggered thrombin generation in vitro.
    Hasan S; Abuelkasem E; Williams B; Henderson R; Mazzeffi MA; Tanaka KA
    Br J Anaesth; 2018 Oct; 121(4):936-943. PubMed ID: 30236256
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prothrombin complex concentrates.
    Penner JA
    Bibl Haematol; 1977; 44():81-7. PubMed ID: 617787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel rat model of thrombogenicity: its use in evaluation of prothrombin complex concentrates and high purity factor IX concentrates.
    McLaughlin LF; Drummond O; MacGregor IR
    Thromb Haemost; 1992 Nov; 68(5):511-5. PubMed ID: 1455396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative in vitro investigation of prothrombin complex concentrates.
    Römisch J; Bonik K; Müller HG
    Semin Thromb Hemost; 1998; 24(2):175-81. PubMed ID: 9579640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heat treated New Zealand factor IX concentrate: comparison with Prothrombinex in patients with haemophilia B.
    Benny AG; Ockelford PA; Johns AS; Woodfield DG; Berry EW
    N Z Med J; 1986 Jun; 99(803):408-9. PubMed ID: 3461352
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heparinised clotting factor concentrates in patients with Christmas disease and liver disease.
    Preston FE; Malia RG; Lilleyman JS; Blackburn EK
    Thromb Haemost; 1977 Aug; 38(2):504-9. PubMed ID: 579492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical efficacy, safety and pharmacokinetic properties of the plasma-derived factor IX concentrate Haemonine in previously treated patients with severe haemophilia B.
    Serban M; Skotnicki AB; Colovic M; Jinca C; Klukowska A; Laguna P; Wolf DM
    Haemophilia; 2012 Mar; 18(2):175-81. PubMed ID: 21812863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human coagulation factor IX: assessment of thrombogenicity in animal models and viral safety.
    Herring SW; Abildgaard C; Shitanishi KT; Harrison J; Gendler S; Heldebrant CM
    J Lab Clin Med; 1993 Mar; 121(3):394-405. PubMed ID: 8445288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factor IX of the blood coagulation system: a review.
    Taran LD
    Biochemistry (Mosc); 1997 Jul; 62(7):685-93. PubMed ID: 9331959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factor IX thrombogenicity: in vivo effects on coagulation activation and a case report of disseminated intravascular coagulation.
    Small M; Lowe GD; Douglas JT; Forbes CD; Prentice CR
    Thromb Haemost; 1982 Aug; 48(1):76-7. PubMed ID: 7135346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of prothrombin complex concentrates in hemophiliacs with inhibitors: clinical and laboratory studies.
    Buchanan GR; Kevy SV
    Pediatrics; 1978 Nov; 62(5):767-74. PubMed ID: 724319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.